{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:18:10Z","timestamp":1778523490620,"version":"3.51.4"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia B is the first bleeding disorder for which gene therapy clinical programs began. Presently, adenovirus-associated vectors represent the best means to deliver the transgene, and their administration by intravenous route has been used in recent clinical trials. The natural occurring factor IX (FIX) Padua variant, which allows for a 5- to 8-fold higher activity of FIX, while maintaining a normal protein concentration, was subsequently used to enhance the level of transgene expression. All the recent trials using this variant showed good results, and accumulating data suggest that long-term expression durability could be maintained at a significant hemostatic level. However, the risk of loss of transgene expression associated to immune response with liver enzymes elevation remains a concern, especially as to the efficacy and duration of immunosuppressive treatment. Notwithstanding this limitation, the results of clinical trials suggest that gene therapy in hemophilia B has the potential to provide long-term benefits with sustained factor activity levels predicted to last several years in many patients.<\/jats:p>","DOI":"10.1055\/s-0044-1787190","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T22:39:31Z","timestamp":1717195171000},"page":"041-048","source":"Crossref","is-referenced-by-count":4,"title":["Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives"],"prefix":"10.1055","volume":"51","author":[{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"Hemophilia Center of the Medical Clinic 2, University Hospital, Frankfurt\/Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"G Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"G Castaman","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"C D Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hae.14675","article-title":"Association of factor expression levels with annual bleeding rate in people with haemophilia B","volume":"29","author":"T Burke","year":"2023","journal-title":"Haemophilia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood.V122.21.2349.2349","article-title":"Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B patients treated with recombinant factor IX Fc fusion protein","volume":"122","author":"A Shapiro","year":"2013","journal-title":"Blood"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.14072","article-title":"Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study","volume":"174","author":"L H Schrijvers","year":"2016","journal-title":"Br J Haematol"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"R Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ejh.14135","article-title":"The current challenges faced by people with hemophilia B","volume":"112","author":"W Miesbach","year":"2024","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JBM.S63265","article-title":"Physical and psychosocial challenges in adult hemophilia patients with inhibitors","volume":"5","author":"S duTreil","year":"2014","journal-title":"J Blood Med"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"D DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"S 2","key":"ref12","first-page":"S11","article-title":"Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status","volume":"90","author":"R Curtis","year":"2015","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"28915","DOI":"10.3402\/qhw.v10.28915","article-title":"Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: results from the HERO qualitative study","volume":"10","author":"L Palareti","year":"2015","journal-title":"Int J Qual Stud Health Well-being"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2040620718791933","article-title":"Gene therapy for hemophilia: what does the future hold?","volume":"9","author":"B S Doshi","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"G Q Perrin","year":"2019","journal-title":"Blood"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"e2020069","DOI":"10.4084\/mjhid.2020.069","article-title":"Gene therapy for hemophilia: facts and quandaries in the 21st century","volume":"12","author":"V R Arruda","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-61779-095-9_9","article-title":"Adeno-associated viruses","volume":"737","author":"M Mezzina","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hum.2015.136","article-title":"Recombinant adeno-associated virus vector genomes take the form of long-lived, transcriptionally competent episomes in human muscle","volume":"27","author":"B C Schnepp","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/JVI.77.6.3495-3504.2003","article-title":"Genetic fate of recombinant adeno-associated virus vector genomes in muscle","volume":"77","author":"B C Schnepp","year":"2003","journal-title":"J Virol"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1073\/pnas.0307833100","article-title":"DNA-dependent PK inhibits adeno-associated virus DNA integration","volume":"101","author":"S Song","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/hum.2020.017","article-title":"The unusual properties of the AAV inverted terminal repeat","volume":"31","author":"K I Berns","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"C Li","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.18609\/cgti.2018.083","article-title":"Overcoming bottlenecks in AAV manufacturing for gene therapy","volume":"4","author":"J M Smith","year":"2018","journal-title":"Cell Gene Ther Insights"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2002-10-3050","article-title":"Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B","volume":"101","author":"L Xu","year":"2003","journal-title":"Blood"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/mthe.2000.0075","article-title":"Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro","volume":"1","author":"C H Miao","year":"2000","journal-title":"Mol Ther"},{"issue":"5879","key":"ref26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/299178a0","article-title":"Molecular cloning of the gene for human anti-haemophilic factor IX","volume":"299","author":"K H Choo","year":"1982","journal-title":"Nature"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"G Buchlis","year":"2012","journal-title":"Blood"},{"issue":"08","key":"ref28","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"C S Manno","year":"2003","journal-title":"Blood"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"C S Manno","year":"2006","journal-title":"Nat Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"L A George","year":"2020","journal-title":"Mol Ther"},{"issue":"25","key":"ref31","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"A C Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"A C Nathwani","year":"2018","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2023-186891","article-title":"Stable therapeutic transgenic FIX levels for more than 10 years in subjects with severe hemophilia B who received scAAV2\/8\u2013LP1-Hfixco adeno-associated virus gene therapy","volume":"142","author":"U M Reiss","year":"2023","journal-title":"Blood"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"W Miesbach","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"S Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref36","first-page":"3","article-title":"First report of a long-term follow-up extension study 6 years after gene therapy with AMT-060 in adults with hemophilia B confirms safety and stable FIX expression and sustained reductions in factor IX use","volume":"1","author":"W Miesbach","year":"2024","journal-title":"Haemophilia"},{"issue":"17","key":"ref37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"P Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector Fidanacogene Elaparvovec and followed for at least 1 year","volume":"134","author":"L A George","year":"2019","journal-title":"Blood"},{"issue":"S 01","key":"ref39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2018-99-118050","article-title":"A single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with haemophilia B","volume":"132","author":"P Chowdary","year":"2018","journal-title":"Blood"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"P Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"ref41","volume-title":"#ISTH2020 - FLT180a Gene Therapy Shows Promise for Hemophilia B Patients in Phase 1\/2 Trial","author":"J Carvalho","year":"2020"},{"issue":"21","key":"ref43","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"A Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"19","key":"ref44","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"A von Drygalski","year":"2023","journal-title":"Blood Adv"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"S W Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"ref46","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"M Schmidt","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"ref49","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"L A George","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"M C Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"ref51","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"L A George","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref52","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"A C Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"ref53","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"S Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"M Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref57","volume-title":"Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial","author":"A Cuker","year":"2023"},{"issue":"S 01","key":"ref58","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of More than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","volume":"138","author":"B J Samelson-Jones","year":"2021","journal-title":"Blood"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/a-1957-4477","article-title":"Gentherapie der H\u00e4mophilie: Empfehlung der Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung (GTH)","volume":"43","author":"W Miesbach","year":"2023","journal-title":"Hamostaseologie"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"H CJ Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"08","key":"ref61","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"J A Greig","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.11.014","article-title":"Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists","volume":"78","author":"W Miesbach","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474086.2023.2276206","article-title":"Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B","volume":"16","author":"G Castaman","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"B A Konkle","year":"2021","journal-title":"Blood"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/hae.14015","article-title":"World Federation of hemophilia gene therapy registry","volume":"26","author":"B A Konkle","year":"2020","journal-title":"Haemophilia"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:37:27Z","timestamp":1737502647000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":60,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787190","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}